174 related articles for article (PubMed ID: 21068803)
21. Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia.
Mizukami K; Sasaki M; Ishikawa M; Iwakiri M; Hidaka S; Shiraishi H; Iritani S
Neurosci Lett; 2000 Apr; 283(2):101-4. PubMed ID: 10739885
[TBL] [Abstract][Full Text] [Related]
22. A GABAergic cortical deficit dominates schizophrenia pathophysiology.
Costa E; Davis JM; Dong E; Grayson DR; Guidotti A; Tremolizzo L; Veldic M
Crit Rev Neurobiol; 2004; 16(1-2):1-23. PubMed ID: 15581395
[TBL] [Abstract][Full Text] [Related]
23. [GABA: a functional duality? Transition during neurodevelopment].
Cortes-Romero C; Galindo F; Galicia-Isasmendi S; Flores A
Rev Neurol; 2011 Jun; 52(11):665-75. PubMed ID: 21563118
[TBL] [Abstract][Full Text] [Related]
24. Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.
Lewis DA; Hashimoto T; Morris HM
Neurotox Res; 2008 Oct; 14(2-3):237-48. PubMed ID: 19073429
[TBL] [Abstract][Full Text] [Related]
25. Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function.
Renard J; Szkudlarek HJ; Kramar CP; Jobson CEL; Moura K; Rushlow WJ; Laviolette SR
Sci Rep; 2017 Sep; 7(1):11420. PubMed ID: 28900286
[TBL] [Abstract][Full Text] [Related]
26. Molecular aspects of age-related cognitive decline: the role of GABA signaling.
McQuail JA; Frazier CJ; Bizon JL
Trends Mol Med; 2015 Jul; 21(7):450-60. PubMed ID: 26070271
[TBL] [Abstract][Full Text] [Related]
27. Modeling GABA alterations in schizophrenia: a link between impaired inhibition and altered gamma and beta range auditory entrainment.
Vierling-Claassen D; Siekmeier P; Stufflebeam S; Kopell N
J Neurophysiol; 2008 May; 99(5):2656-71. PubMed ID: 18287555
[TBL] [Abstract][Full Text] [Related]
28. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study.
Goto N; Yoshimura R; Moriya J; Kakeda S; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Hayashi K; Oonari N; Korogi Y; Nakamura J
Schizophr Res; 2009 Jul; 112(1-3):192-3. PubMed ID: 19464152
[No Abstract] [Full Text] [Related]
29. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
Gaspar PA; Bustamante ML; Silva H; Aboitiz F
J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
[TBL] [Abstract][Full Text] [Related]
30. Schizophrenia and the disconnection hypothesis.
Friston KJ
Acta Psychiatr Scand Suppl; 1999; 395():68-79. PubMed ID: 10225335
[TBL] [Abstract][Full Text] [Related]
31. gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia.
Van Kammen DP
Am J Psychiatry; 1977 Feb; 134(2):138-43. PubMed ID: 835733
[TBL] [Abstract][Full Text] [Related]
32. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling.
Fazzari P; Paternain AV; Valiente M; Pla R; Luján R; Lloyd K; Lerma J; Marín O; Rico B
Nature; 2010 Apr; 464(7293):1376-80. PubMed ID: 20393464
[TBL] [Abstract][Full Text] [Related]
33. [Autism spectrum disorder. Contemporary experimental researches review].
Luschekina EA; Strelets VB
Zh Vyssh Nerv Deiat Im I P Pavlova; 2014; 64(6):585-99. PubMed ID: 25975136
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of GABA and glutamate-receptor subunits and enzymes involved in GABA metabolism between electrophysiologically identified hippocampal CA1 pyramidal cells and interneurons.
Telfeian AE; Tseng HC; Baybis M; Crino PB; Dichter MA
Epilepsia; 2003 Feb; 44(2):143-9. PubMed ID: 12558566
[TBL] [Abstract][Full Text] [Related]
35. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia.
Lewis DA; Pierri JN; Volk DW; Melchitzky DS; Woo TU
Biol Psychiatry; 1999 Sep; 46(5):616-26. PubMed ID: 10472415
[TBL] [Abstract][Full Text] [Related]
36. Alterations of cortical GABA neurons and network oscillations in schizophrenia.
Gonzalez-Burgos G; Hashimoto T; Lewis DA
Curr Psychiatry Rep; 2010 Aug; 12(4):335-44. PubMed ID: 20556669
[TBL] [Abstract][Full Text] [Related]
37. GABAergic drugs and Alzheimer's disease.
Limon A; Reyes-Ruiz JM; Miledi R
Future Med Chem; 2011 Feb; 3(2):149-53. PubMed ID: 21428809
[No Abstract] [Full Text] [Related]
38. Synaptic dysfunction in schizophrenia.
Yin DM; Chen YJ; Sathyamurthy A; Xiong WC; Mei L
Adv Exp Med Biol; 2012; 970():493-516. PubMed ID: 22351070
[TBL] [Abstract][Full Text] [Related]
39. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications.
Maitre M
Prog Neurobiol; 1997 Feb; 51(3):337-61. PubMed ID: 9089792
[TBL] [Abstract][Full Text] [Related]
40. Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions.
Deutsch SI; Rosse RB; Schwartz BL; Mastropaolo J; Burket JA; Weizman A
Isr J Psychiatry Relat Sci; 2010; 47(1):17-26. PubMed ID: 20686196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
